Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/06/2008US20080057010 topical administration of water insoluble extracts from Astragalus membranaceus comprising cycloartane or astragaloside compounds, to improve skin texture, reducing wrinkles, for ultraviolet radiation protection and antiaging effects
03/06/2008US20080057006 genetic vaccines comprising a recombination activating gene (rag) nucleotide sequence, used to code polypeptides, for the prevention and/or treatment of periodontal diseases, caused by infection by Porphyromonas gingivalis
03/06/2008US20080057005 Hydrogels for the controlled release of bioactive materials
03/06/2008US20080057003 Powder inhaler formulations
03/06/2008US20080057002 Non-aqueous compositions containing urea and allantoin and methods for preparing same
03/06/2008US20080056996 Photodynamic therapy for the treatment of hair loss
03/06/2008US20080056993 Post-ischemic myocardial injury; administer a first concurrent parenteral infusion of adenosine and inosine during or following an acute myocardial infarction; protect against reperfusion following ischemic insult in the heart, brain, spinal cord, anti-inflammatory, reduce pain, anesthesia requirements
03/06/2008US20080056991 Histamine H3 receptor inhibitors; (4-Azepan-1-ylmethyl-phenyl)-(4-isopropyl-piperazin-1-yl)-methanone dihydrochloride for example; allergies, nasal congestion, eating disorders, sleep disorders, neurodegenerative disorders
03/06/2008US20080056990 Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability
03/06/2008US20080056988 [18f]-furanosylpurine derivatives and uses thereof
03/06/2008US20080056987 Inhibitor of Eph receptor kinase; treat angiogenesis, lymphangiogenesis or asculogenesis, disorder of the blood vessels, hyperproliferation of body cells, chronic or acute neurodegenerative disorder; enteral, parenteral and oral administration
03/06/2008US20080053430 Aerosol formulation for the inhalation of beta agonists
03/06/2008DE202007016060U1 Topotecan-Basislösung Topotecan-based solution
03/06/2008DE102006039589A1 Aminoacyl-Prodrugs II Aminoacyl prodrugs II
03/06/2008CA2696959A1 Compositions and methods of use thereof for the removal of ticks from epidermal tissue
03/06/2008CA2670271A1 Substituted oxindole derivatives, medicinal products containing them, and use thereof
03/06/2008CA2666469A1 Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
03/06/2008CA2664433A1 Therapeutic methods using wrn binding molecules
03/06/2008CA2662315A1 Solid composites of a calcium receptor-active compound
03/06/2008CA2662298A1 Topical composition comprising a dihydropyridine calcium antagonist
03/06/2008CA2662285A1 Raf inhibitor compounds and methods of use thereof
03/06/2008CA2662274A1 Chemical compounds
03/06/2008CA2662265A1 Imatinib compositions
03/06/2008CA2662260A1 Use of dpa(n-6) oils in infant formula
03/06/2008CA2662219A1 Lyophilized preparation of 1-methylcarbapenem compound
03/06/2008CA2662218A1 Retinoid compounds and their use
03/06/2008CA2662215A1 Novel compositions and methods for treatment of diseases related to activated lymphocytes
03/06/2008CA2662197A1 Pharmaceutical compositions of clonazepam and methods of use thereof
03/06/2008CA2662196A1 Inhibitors of phosphatidylinositol 3-kinase
03/06/2008CA2662185A1 Indoloquinoline compounds as calcium channel blockers
03/06/2008CA2662178A1 Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
03/06/2008CA2662140A1 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
03/06/2008CA2662126A1 Anti cancer use of caffeic acid and its derivatives
03/06/2008CA2662122A1 Controlled release solid oral dosage formulations comprising nisoldipine
03/06/2008CA2662114A1 Agent for treating eye diseases
03/06/2008CA2662086A1 Active pharmaceutical ingredients (apis) with specific water surface areas, pharmaceutical compositions comprising said apis and processes for preparing such compositions and apis
03/06/2008CA2662074A1 Triazole derivatives as kinase inhibitors
03/06/2008CA2661873A1 Cytochrome p450 oxidase inhibitors and uses thereof
03/06/2008CA2661870A1 Substituted benzimidazolone derivatives, medicaments comprising them and their use for treating vasopressin-dependent disease
03/06/2008CA2661863A1 Inhibitors for glyt-1
03/06/2008CA2661850A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
03/06/2008CA2661833A1 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
03/06/2008CA2661800A1 Bifeprunox doses for treating schizophrenia
03/06/2008CA2661776A1 Solid citrate and tartrate salts of dpp-iv inhibitors
03/06/2008CA2661764A1 The antibiotics composition comprising beta-lactam antibiotics and buffers
03/06/2008CA2661754A1 The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents
03/06/2008CA2661702A1 Method for producing phenoxypyridine derivative
03/06/2008CA2661605A1 Hydantoin derivatives useful as antibacterial agents
03/06/2008CA2661598A1 Methods of lowering glucose levels
03/06/2008CA2661590A1 Treating mycobacterial infections with cyclipostins
03/06/2008CA2661582A1 Selective glycosidase inhibitors and uses thereof
03/06/2008CA2661521A1 Pharmaceutical compositions comprising hgh for oral delivery
03/06/2008CA2661494A1 Use of c7 sugars in prevention and treatment of mycoses
03/06/2008CA2661371A1 Pyrimidine compounds for treating gpr119 related disorders
03/06/2008CA2661288A1 Carbamoylsulphoximides as protein kinase inhibitors
03/06/2008CA2661120A1 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
03/06/2008CA2661078A1 Lyophilized preparation
03/06/2008CA2661024A1 Small molecule potentiator of hormonal therapy for breast cancer
03/06/2008CA2660983A1 Polymorph of (r) -3- (2-hydroxy-2, 2-diphenyl-acetoxy) -1- (isoxazol-3-ylcarbamoyl-methyl) -1-azoni a-bicyclo- [2.2.2] octane bromide
03/06/2008CA2660980A1 Pyrrolo isoquinolines as kinase inhibitors
03/06/2008CA2660939A1 Pharmaceutical compositions for the treatment of fungal infections
03/06/2008CA2660806A1 5-substituted isoindoline compounds
03/06/2008CA2660701A1 Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
03/06/2008CA2660699A1 Pyridine compounds for treating gpr119 related disorders
03/06/2008CA2660431A1 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
03/06/2008CA2660376A1 Salts of benzimidazolyl pyridyl ethers and formulations thereof
03/06/2008CA2659770A1 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008CA2659493A1 Spiro antibiotic derivatives
03/06/2008CA2659352A1 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
03/06/2008CA2659339A1 Organic compounds
03/06/2008CA2659144A1 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
03/06/2008CA2657469A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
03/06/2008CA2655241A1 3-(1h-indol-3-yl)indan-1-ylamine derivatives for the treatment of depression and anxiety
03/06/2008CA2649758A1 Preparation and purification of mupirocin calcium
03/06/2008CA2647981A1 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
03/05/2008EP1895012A1 Method for inducing tumor apoptosis by increasing nitric oxide levels
03/05/2008EP1895005A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
03/05/2008EP1894997A1 Improvement of cardiac function by mesenchymal stem cell transplantation
03/05/2008EP1894931A1 Triazole derivatives as kinase inhibitors
03/05/2008EP1894929A1 Process for producing thiazolidinedione compound and production intermediate thereof
03/05/2008EP1894928A1 Heterocyclic fxr binding compounds
03/05/2008EP1894926A1 Polymorphs of moxonidine and processes for preparation therefor
03/05/2008EP1894925A1 Imidazole compounds having an antiinflammatory effect
03/05/2008EP1894924A1 Heterocyclic FXR binding compounds
03/05/2008EP1894921A2 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof
03/05/2008EP1894920A1 Pharmaceutical composition comprising azarhodacyanine compound as active ingredient
03/05/2008EP1894919A1 Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
03/05/2008EP1894918A1 Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)­aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
03/05/2008EP1894917A1 Aryloxy- and arylthioxyacetophenone-type compounds for the treatment of cancer
03/05/2008EP1894916A2 Dicarbonic acid derivatives, metastasis inhibitors and agents increasing chemotherapeutic activity of anti-tumor preparations, method for enhancing the efficiency of cytostatics and metastasis process inhibiting method
03/05/2008EP1894911A1 Vitamin d-like compound
03/05/2008EP1894601A1 Treating mycobacterial infections with cyclipostins
03/05/2008EP1894582A1 Method for control of drug elution rate and composition for coating of drug-eluting stent
03/05/2008EP1894576A1 Novel triglyceride reducing agent
03/05/2008EP1894569A2 Tetracycline derivatives for treating cancer
03/05/2008EP1894568A1 Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
03/05/2008EP1894567A1 Concomitant pharmaceutical agents and use thereof
03/05/2008EP1894566A1 Products containing polyphenol(s) and L-arginine to stimulate nitric oxide production
03/05/2008EP1894565A1 Stabilized milnacipran formulation
03/05/2008EP1894564A2 Use of an ibat inhibitor for the treatment of prophylaxis of constipation